Skip to main content

Table 1 Baseline characteristics of HIV/HBV co-infected patients and by antiretroviral treatment Status

From: Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients

   Treatment status   
Characteristic All patients (N = 235) Experienced (N = 152) Naïve (N = 83) P value T test P value Wilcoxon rank sum test
Mean (SD) age (years) 41.0 (10.0) 42.6 (9.5) 37.9 (10.2) 0.0006 <0.0001
Mean (SD) weight (kg) 63.1 (13.4) 64.9 (13.1) 59.6 (13.2) 0.0038 0.0082
Mean (SD) BMI (kg/m2) 23.4 (4.7) 24.2 (4.7) 21.8 (4.5) 0.0001 0.0002
Mean (SD) CD4 count (cells/uL) 460.7 (322) 513 (304) 363 (334) 0.0006 <0.0001
  n (%) n (%) n (%) P value Chi square P value Fisher
Sex     0.597 0.677
 Female 139 (59.1) 88 (57.9) 51 (61.5)   
 Male 96 (40.9) 64 (42.1) 32 (38.6)   
Ethnicity     0.744 0.762
 Akan 109 (46.8) 72 (47.4) 37 (45.7)   
 Ewe 44 (18.9) 29 (19.1) 15 (18.5)   
 Ga 28 (12.0) 20 (13.1) 8 (9.9)   
 Other 52 (22.3) 31 (20.4) 21 (25.9)   
WHO HIV stage     0.630 0.619
 1 55 (23.7) 38 (25.3) 17 (20.7)   
 2 58 (25.0) 36 (24.0) 22 (26.8)   
 3 92 (39.7) 61 (40.7) 31 (37.8)   
 4 27 (11.6) 15 (10.0) 12 (14.6)   
HBeAg positive 47 (20.0) 28 (18.4) 19 (22.9) 0.413 0.495
HBeAb positive 188 (80.0) 122 (80.3) 66 (79.5) 0.891 1.000
HBeAg/eAb combination     0.622 0.604
HBeAg positive/Ab negative 41 (17.5) 25 (16.5) 16 (19.3)   
HBeAg negative/Ab positive 182 (77.5) 119 (78.3) 63 (75.9)   
HBeAg negative/Ab negative 6 (2.6) 5 (3.3) 1 (1.2)   
HBcIgM positive 5 (2.1) 4 (2.6) 1 (1.2) 0.469 0.659
   Treatment status   
Characteristic All patients Experienced Naïve P value Chi square P value Fisher
N = 235 (%) (N = 152) (N = 83)
n (%) n (%)
Alanine aminotransferase     0.0012 0.0015
 Normal (5-40 U/L) 169 (71.9) 120 (79.0) 49 (59.0)   
 Elevated > ULN 66 (28.1) 32 (21.1) 34 (41.0)   
Aspartate aminotransferase     0.0005 0.0008
 Normal (5-50 U/L) 178 (75.7) 126 (82.9) 52 (62.7)   
 Elevated > ULN 57 (24.3) 26 (17.1) 30 (36.1)   
Albumin     <0.0001 <0.0001
 Normal (36-50) 153 (65.1) 117 (77.0) 36 (43.4)   
 Low < LLN 82 (34.9) 35 (23.0) 47 (56.6)   
HBV DNA (IU mL-1)     <0.0001 <0.0001
  < 20 97 (41.3) 88 (57.9) 9 (10.8)   
 20 – 2000 58 (24.7) 31 (20.4) 27 (32.5)   
 2001 - 20, 000 14 (6.0) 4 (2.6) 10 (12.1)   
  > 20, 000 66 (28.1) 29 (19.1) 37 (44.6)   
Initial ART contain      
 3TC 100 (42.6) 100 (65.8) --   
 3TC + TDF 52 (22.1) 52 (34.2) --   
Duration on ART    --   
<1 year 4 (1.7) 4 (2.6)    
 1 – 2 years 38 (16.2) 38 (25.0) --   
 2 – 3 years 21 (8.9) 21 (13.8) --   
  > 3 years 89 (37.9) 89 (58.6) --   
Ever forgotten meds?   36 (23.7) --   
Do you take meds on time?   16 (10.5) --   
Stop taking meds due to illness?   12 (7.9) --   
Forgotten meds last weekend?   14 (9.2) --   
Number of times not taken meds last week?      
 0   57 (37.5)    
 1 to 2   10 (6.6)    
 3 – 5   6 (3.9)    
 more than 5   3 (2.0)    
  1. BMI body mass index
  2. HBeAg/Ab Hepatitis B e Antigen/Antibody
  3. HBcIgM Hepatitis B core IgM
  4. 3TC lamivudine
  5. TDF tenofovir
  6. ULN upper limit of normal
  7. LLN lower limit of normal
  8. ART anti-retroviral therapy